



The Global Language of Business

# Dispensing Advice Business Message Standard (BMS)

*Release 3.7, Ratified, Mar 2025*



## Document Summary

| Document Item    | Current Value                                     |
|------------------|---|
| Document Name    | Dispensing Advice Business Message Standard (BMS) |
| Document Date    | Mar 2025  |
| Document Version | 3.7   |
| Document Issue   | 1   |
| Document Status  | Ratified  |

## Work Request Reference

| Date of WR Submission to GSMP: | WR Submitter(s): | Refer to Work Request (WR) Number(s): |
|--------------------------------|------------------|---------------------------------------|
|                                |                  |                                       |
|                                |                  |                                       |
|                                |                  |                                       |

## Business Requirements Document (BRAD) Reference

| BRAD Title | BRAD Issue Date | BRAD Version |
|------------|-----------------|--------------|
|            |                 |              |

## Document Change History

| Date of Change | Version   | Changed By               | Reason for Change                | Summary of Change  |
|----------------|-----------|--------------------------|----------------------------------|--|
| 3-Apr-2020     | BMS 3.4.2 | Mark Van Eeghem          | Initial Draft                    | Initial Draft  |
| 10-Aug-2020    | BMS 3.4.2 | Piergiorgio Licciardello | Updates after group revision     | Attributes and class definitions, examples                               |
| 24-Sep-2020    | BMS 3.4.2 | Piergiorgio Licciardello | Group revision                   |  |
| 14-Oct-2020    | BMS 3.4.2 | Piergiorgio Licciardello | Updates after community revision | Change protocolIdentification in protocolID, add GLN in site description |
| 29-Oct-2020    | BMS 3.4.2 | Piergiorgio Licciardello | Errata corrige                   | Class diagram update   |
| 15-Jan-2021    | BMS 3.5   | Miklos Bolyky            | BMS Release 3.5                  | See summary of changes   |
| 05-Jan-2022    | BMS 3.5.1 | Miklos Bolyky            | BMS Release 3.5.1                | See summary of changes   |
| 01-Mar-2023    | BMS 3.6   | Miklos Bolyky            | BMS Release 3.6                  | See summary of changes   |
| 15-Mar-202     | BMS 3.7   | Miklos Bolyky            | BMS Release 3.7                  | See summary of changes   |



## Disclaimer

GS1 seeks to minimise barriers to the adoption of its standards and guidelines by making the intellectual property required to implement them available, to the greatest extent possible, on a royalty-free basis, or when necessary, under a RAND licence. Such royalty-free and RAND licences are provided pursuant to the GS1 IP Policy (available here: <https://www.gs1.org/standards/ip>), which governs the work of work group participants who contribute to drafting standards and guidelines, including this document. In addition to licences, the GS1 IP Policy provides various benefits and obligations that apply to all implementers of GS1 standards and guidelines, and all implementations of GS1 standards are subject to those terms.

Nevertheless, please note the possibility that an implementation of one or more features of this standard or guideline may be the subject of a patent or other intellectual property right that is not covered by the licences granted pursuant to the IP Policy. In addition, the licences granted under the IP Policy do not include the IP rights or claims of third parties who were not participants in the corresponding standard development work group.

Accordingly, GS1 recommends that any person or organisation developing an implementation of this standard or guideline should determine whether any patents or other intellectual property may encompass such implementation, and whether a licence under a patent or other IP right is needed. The implementer should determine the potential need for licensing in view of the details of the specific implementation being designed in consultation with that party's patent counsel.

The official versions of all GS1 standards and guidelines are provided as PDF files on GS1's online reference directory (<https://ref.gs1.org>) (the "GS1 Reference"). Any other representations of standards or guidelines in any other format (e.g., web pages) are provided for convenience and descriptive purposes only, and in the event of a conflict, the GS1 Reference document shall govern.

THIS DOCUMENT IS PROVIDED "AS IS" WITH NO WARRANTIES WHATSOEVER, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR PARTICULAR PURPOSE, ACCURACY OR COMPLETENESS, OR ANY WARRANTY OTHERWISE ARISING OUT OF THIS DOCUMENT. GS1 disclaims all liability for any damages arising from any use or misuse of this document, whether special, indirect, consequential, or compensatory damages, and including liability for infringement of any intellectual property rights, relating to use of information in or reliance upon this document.

GS1 makes no commitment to update the information contained herein, and retains the right to make changes to this document at any time, without notice. GS1® and the GS1 logo are registered trademarks of GS1 AISBL.

## Table of Contents

|          |                                      |           |
|----------|--------------------------------------|-----------|
| <b>1</b> | <b>Business Domain View</b>          | <b>5</b>  |
| 1.1      | Introduction                         | 5         |
| 1.2      | References                           | 5         |
| <b>2</b> | <b>Business Context</b>              | <b>5</b>  |
| <b>3</b> | <b>Business Transaction View</b>     | <b>6</b>  |
| <b>4</b> | <b>Business Information View</b>     | <b>8</b>  |
| 4.1      | Dispensing Advice                    | 8         |
| 4.2      | Enumerations (message specific)      | 13        |
| 4.3      | Code Lists                           | 13        |
| <b>5</b> | <b>Business Message Examples</b>     | <b>13</b> |
| 5.1      | Example 1                            | 13        |
| <b>6</b> | <b>Implementation Considerations</b> | <b>14</b> |



|          |                                       |           |
|----------|---------------------------------------|-----------|
| 6.1      | User Guide .....                      | 14        |
| 6.2      | Message Specific Considerations ..... | 15        |
| <b>7</b> | <b>Summary of Changes .....</b>       | <b>15</b> |
| 7.1      | BMS Release 3.4.2 .....               | 16        |
| 7.2      | BMS Release 3.5 .....                 | 16        |
| 7.3      | BMS Release 3.5.1 .....               | 16        |
| 7.4      | BMS Release 3.6 .....                 | 16        |
| 7.5      | BMS Release 3.7 .....                 | 16        |
| <b>8</b> | <b>Appendices .....</b>               | <b>17</b> |
| <b>9</b> | <b>Acknowledgements.....</b>          | <b>17</b> |
| 9.1.1    | Work Group .....                      | 17        |
| 9.1.2    | Development Team Members .....        | 19        |

# 1 Business Domain View

## 1.1 Introduction

### Purpose

The Dispensing Advice is used to communicate information related to the specific Investigational Products (IP) assigned to patients within the trial. This Dispensing Advice Business Message Standard is one part of a suite of documents designed to provide the detailed technical mappings to GS1 message formats for EDI messages being implemented for Clinical Trials.

The other documents in this suite are:

- Inventory Release
- Shipment Request
- Shipment Notification
- Shipment Confirmation
- Despatch Advice
- Receiving Advice
- Request for Inventory Report
- Inventory Report
- Kit Status Change

### Scope

The scope of this work includes all messages identified in [the GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline](#), hereafter called 'the Guideline', section 4.2.

### Considerations

The workgroup that developed this mapping document has ensured that the messages and associated mappings are technology and sponsor agnostic.

It is important that organisations implementing electronic business messaging in line with this guideline undertake an appropriate assessment to ensure that the blinding status of the trial is respected in the messages exchanged.

Messaging communications with transport providers / couriers / carriers are out of scope because there are already electronic processes in place and altering them would not add value.

## 1.2 References

| Reference Name   | Description   |
|--|---|
| <a href="#">GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline</a> , | The guideline details the business requirement of the clinical trials context, both in terms of process design and data set shared between the actors |
|  |   |
|  |   |
|  |   |

# 2 Business Context


| Context Category | Value(s)                                      |
|------------------|---|
| Industry         | Healthcare, Pharmaceuticals & Medical Devices |

| Context Category     | Value(s)        |
|----------------------|-----------------|
| Geopolitical         | All             |
| Product              | All             |
| Process              | Clinical Trials |
| System Capabilities  | GS1 System      |
| Official Constraints | None            |

### 3 Business Transaction View

#### Business Process Participants

As detailed in *the Guideline*, section 4.1, the diagram and table below provide an overview of the main actors involved in the process.



**Table 3-1** Roles and responsibilities

| Role                                      | Responsibility in process  |
|---|--|
| Manufacturer/sponsor                      | Has overall responsibility for the trial, produces the Investigational Product (IP)  |
| Contract Manufacturing Organisation (CMO) | Manufactures and may package IP and IP kits at the direction of the manufacturer/sponsor   |
| Packaging site                            | Packages and labels the IP and IP kits   |
| Distributor (with warehouse)              | Warehouses and distributes the IP kits as needed to the sites  |
| Carrier (transporting the goods)          | Logistics provider moving the IP kits at the request of other stakeholders   |
| Clinical trial site                       | The healthcare provider location where the trial is conducted and dispensing to the patient typically occurs   |
| Return facility                           | Responsible for receipt of any IP kits returned from trial sites   |
| Distribution Management Entity (DME)      | A term used to identify the system(s) managing, distribution, and disposition of clinical supplies. In many cases this is the interactive technology IRT system, portal, a set of tools or different databases used to share information during a clinical trial, etc. |

## Use Case Diagram

N/A

## Use Case Description

Below is the use case detailed in *the Guideline*, section 7.10

| Performance goals    | Accurate recording of items to be or that have been dispensed. This will provide accurate use information for planning activities, etc.  |                             |       |               |   |          |                             |
|----------------------|--|-----------------------------|-------|---------------|---|----------|-----------------------------|
| Preconditions        | Unique identification of locations, trade items and logistics units will be undertaken. Correct identification receiver (Ship To/inventory location) are in place.   |                             |       |               |   |          |                             |
| Postconditions       | None identified  |                             |       |               |   |          |                             |
| Scenario             | <p>Begins when the sponsor sends a communication to the trial site to advise which specific IP kit must be dispensed to a specific patient.</p> <p>Continues with...</p> <table><tr><th>Step #</th><th>Actor</th><th>Activity step</th></tr><tr><td>1</td><td>Receiver</td><td>Receives the communication.</td></tr></table> <p>Ends when the receiver takes action to dispense the correct kit to the correct patient.</p>      | Step #                      | Actor | Activity step | 1 | Receiver | Receives the communication. |
| Step #               | Actor  | Activity step               |       |               |   |          |                             |
| 1                    | Receiver   | Receives the communication. |       |               |   |          |                             |
| Alternative Scenario | <p>Begins when the trial site sends a communication to the sponsor to advise which specific IP kit has been dispensed to a specific patient.</p> <p>Continues with...</p> <table><tr><th>Step #</th><th>Actor</th><th>Activity step</th></tr><tr><td>1</td><td>Receiver</td><td>Receives the communication.</td></tr></table> <p>Ends when the receiver takes action to record that dispensing activity in their IT systems.</p> | Step #                      | Actor | Activity step | 1 | Receiver | Receives the communication. |
| Step #               | Actor  | Activity step               |       |               |   |          |                             |
| 1                    | Receiver   | Receives the communication. |       |               |   |          |                             |
| Related requirements | If the direction of the dispensing advice message is from trial site to sponsor confirming which drug given to the patient, consider including the staff ID of who did the dispensing.   |                             |       |               |   |          |                             |
| Related rules        | None identified  |                             |       |               |   |          |                             |

## Activity Diagram(s)

Not applicable

## Sequence Diagram(s)


Not applicable

## **4 Business Information View**

### **4.1 Dispensing Advice**

**Class diagram**





The content of the DispensingAdvice class, its structure and component definitions can be accessed in the GS1 Navigator:

[Navigator link](#)

| Content                           | Attribute / Role               | Datatype / Secondary class          | Multiplicity | Definition   | Constraints |
|-----------------------------------|--------------------------------|-------------------------------------|--------------|--|-------------|
| <b>DispensingAdvice</b>           |                                |                                     |              | The Dispensing Advice is used to communicate information related to the specific IPs assigned to patients within the trial |             |
| ASSOCIATION                       | GENERALIZATION                 | EcomDocument                        | 1..1         |  |             |
| ASSOCIATION                       | dispensingAdviceIdentification | Ecom_EntityIdentification           | 1..1         | The identification of the dispensing advice message  |             |
| ASSOCIATION                       | sender                         | Ecom_PartyIdentification            | 0..1         | The entity sending the dispensing instruction or the information about the dispensing execution                            |             |
| ASSOCIATION                       | receiver                       | Ecom_PartyIdentification            | 0..1         | The entity receiving the dispensing instructions or the dispensing execution information                                   |             |
| ASSOCIATION                       |                                | DispensingForPharmacyOrder          | 0..*         | Dispensing instructions for the use case where clinical pharmacy identifies the quantity and materials dispensed           |             |
| ASSOCIATION                       |                                | DispensingForDMEOrder               | 0..*         | Dispensing instructions for the use case where the DME dictates the quantity and materials dispensed                       |             |
| ASSOCIATION                       |                                | MaterialIssuedtoPatientConfirmation | 0..*         | The detail of dispensed kits   |             |
| ATTRIBUTE                         | protocolID                     | string                              | 1..1         | The identification of the protocol   | {1..20}     |
| ATTRIBUTE                         | protocolOwner                  | GLN                                 | 1..1         | The identification of the owner of the protocol  |             |
| <b>DispensingForPharmacyOrder</b> |                                |                                     |              |  |             |
| ASSOCIATION                       | site                           | Ecom_PartyIdentification            | 1..1         | The GLN of the site where the kits are dispensed   |             |
| ASSOCIATION                       |                                | AdditionalSubjectInformation        | 0..*         |  | WR 22-350   |

| Content                                    | Attribute / Role                     | Datatype / Secondary class             | Multiplicity | Definition   | Constraints |
|--|--------------------------------------|--|--------------|--|-------------|
| ATTRIBUTE                                  | investigationalProductIdentification | gtin                                   | 1..1         | The GTIN of the investigational product                            |             |
| ATTRIBUTE                                  | kitSerialNumber                      | string                                 | 1..*         | The serial number of the kit                                       | {1..20}     |
| ATTRIBUTE                                  | subjectIdentification                | string                                 | 1..1         | The identification of the patient                                  | {1..200}    |
| ATTRIBUTE                                  | subjectWeight                        | Measurement                            | 0..1         | The weight of the patient  |             |
| ATTRIBUTE                                  | quantity                             | Quantity                               | 1..1         | The quantity of IP to dispense to the patient                      |             |
| <b>AdditionalSubjectInformation</b>        |                                      |  |              |  | WR 22-350   |
| ATTRIBUTE                                  | subjectMeasurementQualifierCode      | SubjectMEasurementQualifierCode        | 1..1         | The code specifying the type of measurement provided               | WR 22-350   |
| ATTRIBUTE                                  | subjectMeasurement                   | Measurement                            | 0..1         | The value of the measurement related to the patient                | WR 22-350   |
| ATTRIBUTE                                  | subjectGender                        | ClinicalTrialGenderEnumeration         | 0..1         | The gender of the patient  | WR 22-350   |
| <b>DispensingForDMEOOrder</b>              |                                      |  |              |  |             |
| ASSOCIATION                                | site                                 | Ecom_PartyIdentification               | 1..1         | The GLN of the site where the kits are dispensed                   |             |
| ASSOCIATION                                |                                      | SerializedInvestigationalProductKit    | 0..*         | Set of information identifying the serialized kits to dispense     |             |
| ASSOCIATION                                |                                      | NotSerializedInvestigationalProductKit | 0..*         | Set of information identifying the non-serialized kits to dispense |             |
| ATTRIBUTE                                  | subjectIdentification                | string                                 | 1..1         | The identification of the patient                                  | {1..200}    |
| <b>MaterialIssuedtoPatientConfirmation</b> |                                      |  |              |  |             |
| ASSOCIATION                                | site                                 | Ecom_PartyIdentification               | 1..1         | The GLN of the site where the kits are dispensed                   |             |
| ASSOCIATION                                |                                      | SerializedInvestigationalProductKit    | 0..*         | Set of information identifying the serialized kits to dispense     |             |

| Content                                       | Attribute / Role                     | Datatype / Secondary class             | Multiplicity | Definition   | Constraints |
|---|--------------------------------------|--|--------------|--|-------------|
| ASSOCIATION                                   |                                      | NotSerialisedInvestigationalProductKit | 0..*         | Set of information identifying the non-serialized kits to dispense |             |
| ATTRIBUTE                                     | subjectIdentification                | string                                 | 1..1         | The identification of the patient                                  | {1..200}    |
| ATTRIBUTE                                     | dateOfDispensing                     | DateTime                               | 1..1         | The date when the kits have been dispensed to the patient          |             |
| <b>SerialisedInvestigationalProductKit</b>    |                                      |  |              |  |             |
| ATTRIBUTE                                     | investigationalProductIdentification | gtin                                   | 1..1         | The GTIN of the investigational product                            |             |
| ATTRIBUTE                                     | kitSerialNumber                      | string                                 | 1..*         | The serial number of the kit                                       | {1..20}     |
| ATTRIBUTE                                     | kitLotNumber                         | string                                 | 0..1         | The batch/lot number of the kit                                    | {1..20}     |
| <b>NotSerialisedInvestigationalProductKit</b> |                                      |  |              |  |             |
| ATTRIBUTE                                     | investigationalProductIdentification | gtin                                   | 1..1         | The GTIN of the investigational product                            |             |
| ATTRIBUTE                                     | kitLotNumber                         | string                                 | 0..1         | The batch/lot number of the kit                                    | {1..20}     |
| ATTRIBUTE                                     | quantity                             | Quantity                               | 1..1         | The quantity of IP dispensed / to dispense                         |             |

## 4.2 Enumerations (message specific)

| Class                        | Codelist      | Values  |
|------------------------------|---------------|---|
| AdditionalSubjectInformation | subjectGender | <a href="https://navigator.gs1.org/edi/attribute-details?parent=AdditionalSubjectInformation&amp;name=subjectGender">https://navigator.gs1.org/edi/attribute-details?parent=AdditionalSubjectInformation&amp;name=subjectGender</a> |

## 4.3 Code Lists

| Class                        | Codelist                        | Navigator Link   |
|------------------------------|---------------------------------|--|
| AdditionalSubjectInformation | subjectMeasurementQualifierCode | <a href="https://navigator.gs1.org/edi/codelist-details?name=SubjectMeasurementQualifierCode">https://navigator.gs1.org/edi/codelist-details?name=SubjectMeasurementQualifierCode</a><br><br>Note:<br>If subjectMeasurementQualifierCode equals "GENDER" then subjectGender must be populated and subjectMeasurement must be empty. If subjectMeasurementQualifierCode equals any other value, then subjectGender must not be populated and subjectMeasurement must be used. |
|                              |                                 |  |
|                              |                                 |  |
|                              |                                 |  |



**Note:** Refer to the GS1 Navigator (Navigator) for the code values.

# 5 Business Message Examples

## 5.1 Example 1

This example maps the use case "scenario 1" as defined in the section 7.10.3 of the message implementation guideline. The message 1 maps the dispensing instructions from DME to clinical pharmacy and the message 2 is the dispensing confirmation from clinical pharmacy to DME

### Party Information

| GS1 Global Location Number | Party Type                              |
|----------------------------|---|
| 9520000000011              | Sender of dispensing instructions DME   |
| 9520000000028              | Organisation receiving the instructions |
| 9520000000004              | Protocol sponsor                        |
| 9520000000127              | Clinical Pharmacy location              |

### Message Example 1

| Attribute                             | Value         |
|---------------------------------------|---------------|
| <b>DispensingAdvice</b>               |               |
| <i>dispensingAdviceIdentification</i> |               |
| entityIdentification                  | 3             |
| <i>sender</i>                         |               |
| GLN                                   | 9520000000011 |
| <i>receiver</i>                       |               |

| Attribute                            | Value         |
|--------------------------------------|---------------|
| GLN                                  | 9520000000028 |
| protocolID                           | PROT1         |
| protocolOwner                        | 9520000000004 |
| <b>DispensingForPharmacyOrder</b>    |               |
| <b>site</b>                          |               |
| GLN                                  | 9520000000127 |
| investigationalProductIdentification | 9520000000530 |
| kitSerialNumber                      | 1243          |
| subjectIdentification                | M254          |
| subjectWeight                        | 85            |
| <b>quantity</b>                      |               |
| quantity                             | 1             |
| measurementUnitCode                  | H87           |
|                                      |               |

### Message Example 2

| Attribute                                  | Value                   |
|--|-------------------------|
| <b>DispensingAdvice</b>                    |                         |
| <b>dispensingAdviceIdentification</b>      |                         |
| entityIdentification                       | 5                       |
| <b>sender</b>                              |                         |
| GLN  | 9520000000028           |
| <b>receiver</b>                            |                         |
| GLN  | 9520000000011           |
| protocolID                                 | PROT1                   |
| protocolOwner                              | 9520000000004           |
| <b>MaterialIssuedtoPatientConfirmation</b> |                         |
| <b>site</b>                                |                         |
| GLN  | 9520000000127           |
| subjectIdentification                      | M254                    |
| dateOfDispensing                           | 2020-08-14T00:00:00.000 |

## 6 Implementation Considerations

### 6.1 User Guide


All implementation considerations are discussed in [the GS1 Pharmaceutical Clinical Trial Electronic Messaging Standard Implementation Guideline](#).

## 6.2 Message Specific Considerations

The structure of the Dispensing Advice is multifunctional, depending on the direction of the message and the function.

The DME can generate two kind of dispensing instructions, mapping two scenarios, and the structure of the detail section changes.

The dispensing confirmation maps a third possible structure applicable in the flow from clinical pharmacy to DME



## 7 Summary of Changes

Any change in the GS1 standards is done based on the Work Request (WR) submitted by the GS1 User Companies or Member Organisations. All Work Requests are documented in the Work Request system available on the GS1 website: <http://wr.gs1.org>. The system is accessible to registered users. New visitors need to register first, to be able to access it. WRs can be searched by the number referenced in tables below, see: Search Work Requests. The number starts with the two last digits of the year when it was submitted, followed by the consecutive number within that year.



**Note:** WRs submitted earlier than February 2012 should be searched in Old Change Requests.

## 7.1 BMS Release 3.4.2

| Change  | Associated CR Number |
|---|----------------------|
| <ul style="list-style-type: none"> <li>Initial Draft</li> </ul> |                      |


## 7.2 BMS Release 3.5

No work requests. Indirect changes due to upgrade to new Shared and eCom Common libraries.

## 7.3 BMS Release 3.5.1

No work requests. Indirect changes due to upgrade to new Shared and eCom Common libraries.

## 7.4 BMS Release 3.6

| Change   | Associated CR Number |
|--|----------------------|
| <ul style="list-style-type: none"> <li>New class <b>AdditionalSubjectInformation</b> created<br/>New association from DispensingForPharmaOrder to AdditionalSubjectInformation created</li> </ul>  | WR-22-350            |
| <ul style="list-style-type: none"> <li>New codelist <b>subjectMeasurementQualifierCode</b> added to new class.<br/>new measurement <b>subjectMeasurement</b> which has cardinality 0..1 added to new class.<br/>new enumeration added <b>subjectGender</b> to new class with cardinality 0..1</li> </ul> | WR-22-350            |
| <ul style="list-style-type: none"> <li>Snipped for specific section below: <div data-bbox="316 1106 1273 1727" data-label="Diagram">  </div> </li> </ul>   | WR-22-350            |

## 7.5 BMS Release 3.7

| Change   | Associated CR Number |
|--|----------------------|
| <ul style="list-style-type: none"> <li>Changed the cardinality of <b>sender</b> and <b>receiver</b> from 1..1 to 0..1</li> </ul> | WR-24-000186         |



## 8 Appendices

Not Applicable

## 9 Acknowledgements

### 9.1.1 Work Group

| Function         | Name                               | Company / organisation                   |
|------------------|------------------------------------|--|
| <b>WG chair</b>  | Olivia Chauvel (Chair)             | CH Victor Dupouy                         |
| <b>WG chair</b>  | Pierre Fernandez-Barbureau (Chair) | SANOFI                                   |
| <b>WG chair</b>  | Hans von Steiger (Chair)           | Pfizer                                   |
| <b>WG member</b> | Jean-Michel Descoutures            | International Hospital Federation (IHF)  |
| <b>WG member</b> | Feargal Mc Groarty                 | St. James's Hospital                     |
| <b>WG member</b> | Vincent Puglia                     | endpoint clinical                        |
| <b>WG member</b> | Mike Meakin                        | DHL                                      |
| <b>WG member</b> | Sylvain Alberola                   | SANOFI                                   |
| <b>WG member</b> | Céline Bordes-Terrier              | CREAPHARM                                |
| <b>WG member</b> | Giedré Bracaité                    | F. Hoffmann-La Roche Ltd.                |
| <b>WG member</b> | Doris Cadart                       | SANOFI                                   |
| <b>WG member</b> | Pedro Carvalho                     | Ipsen                                    |
| <b>WG member</b> | Robert Giguere                     | AbbVie                                   |
| <b>WG member</b> | Nicolas Gryspeert                  | F. Hoffmann-La Roche Ltd.                |
| <b>WG member</b> | Michael Hoefling                   | Boehringer Ingelheim Pharma GmbH & Co.KG |
| <b>WG member</b> | Richard Hwang                      | Pfizer                                   |
| <b>WG member</b> | Marco Inserra                      | CSL Behring GmbH                         |
| <b>WG member</b> | Jason James                        | Bristol-Myers Squibb                     |
| <b>WG member</b> | Matthias Kallmeyer                 | Boehringer Ingelheim Pharma GmbH & Co.KG |
| <b>WG member</b> | Nicolas Le Rudlier                 | CREAPHARM                                |
| <b>WG member</b> | Yann Montcourt                     | Ipsen                                    |
| <b>WG member</b> | Barry Moore                        | GlaxoSmithKline                          |
| <b>WG member</b> | Marianne Perdrijat                 | DBV TECHNOLOGIES                         |
| <b>WG member</b> | Amy Rupp                           | CSL Behring GmbH                         |
| <b>WG member</b> | Amanda Scott                       | Biogen                                   |
| <b>WG member</b> | Jodi Smith-Gick                    | Eli Lilly and Company                    |
| <b>WG member</b> | Richard Austin                     | PAREXEL International GmbH               |
| <b>WG member</b> | Nick Bobrinskoy                    | nCoup, Inc.                              |
| <b>WG member</b> | Arpad Boldis                       | Deloitte                                 |
| <b>WG member</b> | Robert Celeste                     | Center for Supply Chain Studies          |

| Function         | Name                    | Company / organisation                  |
|------------------|-------------------------|---|
| <b>WG member</b> | Dilip Daswani           | Qliktag Software (formally Zeebric LLC) |
| <b>WG member</b> | Andreas Geissler        | PAREXEL International GmbH              |
| <b>WG member</b> | Mark Hanly              | Almac Clinical Technologies             |
| <b>WG member</b> | Mike Hutton             | Almac Clinical Technologies             |
| <b>WG member</b> | Kelly Knowles           | Bracket Global                          |
| <b>WG member</b> | Jitendra Kumar          | Thermo Fisher Scientific                |
| <b>WG member</b> | Cherish Lallone         | McCreadie Group                         |
| <b>WG member</b> | Charlotte Meuldermans   | Deloitte                                |
| <b>WG member</b> | Fabiana Monaco          | PAREXEL International GmbH              |
| <b>WG member</b> | Josef Preishuber-Pflügl | CISC Semiconductor GmbH                 |
| <b>WG member</b> | Theodora Sarver         | Almac Clinical Technologies             |
| <b>WG member</b> | Michael schlesselman    | McCreadie Group                         |
| <b>WG member</b> | Colette Thorold         | PAREXEL International GmbH              |
| <b>WG member</b> | Elizabeth Waldorf       | TraceLink                               |
| <b>WG member</b> | Stefan Zietze           | PAREXEL International GmbH              |
| <b>WG member</b> | Andrea Zobel            | PAREXEL International GmbH              |
| <b>WG member</b> | Shreenidhi Bharadwaj    | Syndigo                                 |
| <b>WG member</b> | Tony Zhang              | Syndigo                                 |
| <b>WG member</b> | Richard Perkins         | eClinical Forum                         |
| <b>WG member</b> | Olivier Mary            | COLCA Medical & Scientific              |
| <b>WG member</b> | Preedee Chenhansa       | Tenthpin                                |
| <b>WG member</b> | Poppy Abeto Kiese       | GS1 Austria                             |
| <b>WG member</b> | Andrea Arozamena        | GS1 Mexico                              |
| <b>WG member</b> | Mahdi Barati            | GS1 Iran                                |
| <b>WG member</b> | Jiraporn Chalermjirarat | GS1 Thailand                            |
| <b>WG member</b> | Shawn Chen              | GS1 Thailand                            |
| <b>WG member</b> | Mignone Cheng           | GS1 Hong Kong, China                    |
| <b>WG member</b> | Luiz Costa              | GS1 Brasil                              |
| <b>WG member</b> | Sandra Couto            | GS1 Canada                              |
| <b>WG member</b> | Jesper Kervin Franke    | GS1 Denmark                             |
| <b>WG member</b> | Stefan Gathmann         | GS1 Ireland                             |
| <b>WG member</b> | Nicole Golestani        | GS1 Canada                              |
| <b>WG member</b> | Rami Habbal             | GS1 UAE                                 |
| <b>WG member</b> | Michaela Hähn           | GS1 Germany                             |
| <b>WG member</b> | Christine Horvath-Hanko | GS1 Hungary                             |
| <b>WG member</b> | Anna Klapper            | GS1 Germany                             |
| <b>WG member</b> | Catherine Koetz         | GS1 Australia                           |
| <b>WG member</b> | Anne-Claire Krid        | GS1 France                              |
| <b>WG member</b> | Camille Labeaune        | GS1 France                              |
| <b>WG member</b> | Ildikó Lieber           | GS1 Hungary                             |
| <b>WG member</b> | Valerie Marchand        | GS1 France                              |

| Function         | Name              | Company / organisation |
|------------------|-------------------|------------------------|
| <b>WG member</b> | Adrien Molines    | GS1 France             |
| <b>WG member</b> | Zubair Nazir      | GS1 Canada             |
| <b>WG member</b> | Alice Nguyen      | GS1 Vietnam            |
| <b>WG member</b> | James Perng       | GS1 Chinese Taipei     |
| <b>WG member</b> | James Perng       | GS1 Chinese Taipei     |
| <b>WG member</b> | Paul Reid         | GS1 UK                 |
| <b>WG member</b> | Sylvia Reingardt  | GS1 Germany            |
| <b>WG member</b> | Sue Schmid        | GS1 Australia          |
| <b>WG member</b> | Julian Sin        | GS1 Hong Kong, China   |
| <b>WG member</b> | Mig Smith         | GS1 UK                 |
| <b>WG member</b> | Peter Sturtevant  | GS1 US                 |
| <b>WG member</b> | Flora Sue         | GS1 China              |
| <b>WG member</b> | Sarah Torrance    | GS1 UK                 |
| <b>WG member</b> | Koichi Uemura     | GS1 Japan              |
| <b>WG member</b> | Amber Walls       | GS1 US                 |
| <b>WG member</b> | Connie Wong       | GS1 Canada             |
| <b>WG member</b> | Pete Alvarez      | GS1 Global Office      |
| <b>WG member</b> | Jean-Luc Champion | GS1 Global Office      |
| <b>WG member</b> | Steven Keddie     | GS1 Global Office      |
| <b>WG member</b> | Neil Piper        | GS1 Global Office      |
| <b>WG member</b> | Greg Rowe         | GS1 Global Office      |
| <b>WG member</b> | Tania Snioch      | GS1 Global Office      |

### 9.1.2 Development Team Members

| Function                   | Name            | Organisation      |
|----------------------------|-----------------|-------------------|
| GSMP Process Lead          | David Buckley   | GS1 Global Office |
| Technical Development Lead | Miklos Bolyky   | GS1 Global Office |
| Peer Review                | Mark Van Eeghem | GS1 Global Office |